+ 1 303 249 9174
FloydTaub@ai-gene.us

aiGENE

A rapid universal blood test measuring cancer and cancer treatment effectiveness

ACTIONABLE INFORMATION FROM THE EPIGENE

Our Dream

Rapid, inexpensive, universal, on-site, pan-cancer evaluation; ultimately an inexpensive, universal, pan-cancer screening test.

Press Release July 9, 2020

"License agreement creates golden opportunity for cancer diagnostic technology!"

A novel rapid cancer diagnostic technology with the potential to quickly and easily detect cancer has been licensed for further development.

Our technology

AN ELECTRODE BASED METER THAT GENERATES A DIGITAL READOUT BASED ON THE AMOUNT OF CANCER DNA IN A PERSON’S BLOOD

THE "aiELECTRODE" IS SELECTIVELY SENSITIVE TO THE ALTERED METHYLATION PATTERN THAT IS CHARACTERISTIC OF ALL TYPES OF CANCER DNA TESTED.

MethylScape concept

Literature confirmation

“…tumor cells generally exhibit genome-wide hypomethylation and localized hypermethylation….

Thus, the identification of epigenetic alterations “…improved cancer diagnosis and effective treatments”

Zhang W1, Xu J1.
Biomark Res. 2017; 5: 1.

Our technology

How does it work?

The electrode's ability to separate blood from cancer patients and normal patients is extraordinary

Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker

p value less than 10 e-15

Summary of our technology and potential uses

Therascape

Watch your treatment work!

Target, Kill and Confirm.

Typically, it takes 3-6 months for scans to show if a cancer is shrinking. "Pseudo-progression" is the term used when scans are wrong, showing an increase in size despite effective therapy.

TheraScape provides a true reading of cancer DNA from a simple blood test. The first use of TheraScape will be in trials of new drugs. Pharma wants to know early if a drug is working. Clinical trial research use is not FDA regulated.

CLIA lab(s) can provide the testing to doctors and patients so every person can be sure their therapy is working.

Current “personalized medicine” predicts which therapy will work for a cancer patient, unfortunately, like most predictions, it is inaccurate. For advanced cancers, although it improves the odds, more often it is wrong than right.

aiGENE does not predict, it measures. This “in-persona evaluation™” will provides accurate evaluation of immunotherapy before a second dose. TheraScape will enable an immediate and lifesaving switch.

Ultimately every oncologist will be able to do this test in their office and we believe will do it on all eligible patients before every new round of therapy.

Executive Team

Dr. Floyd Taub

CEO
  • Northwestern University. M.D.
  • University of Colorado Medical Center
  • George Washington University
  • National Institutes of Health (NIH) including heading a pathology unit. 
  • Founder of Digene, the company that changed the screening for cervical cancer. Digene developed the first clinical nucleic acid test for cancer or precancer. HPV is still the most used test for cancer.
  • CEO of CytoCore, CYOE. 
  • Head biomedical scientist/pathologist at OTraces, Veramarx, ClearCreek Partners, AccuBiome and AxImmune.
  • Founder of Dovetail Technologies, LifeTime Pharmaceuticals and FindCure.Org, the organizations that coordinated to take the first drug that modulates immune checkpoint molecules into clinical trials.
  • Over 50 publications, presentations and patent applications

Stan Lapidus

Advisor
  • Executive-in-Residence at CU Innovations
  • Founder, CEO and board member of medical diagnostics and device companies for over 30 years.
  • Founder of Cytyc Corp (NASDA :CYTC He is the principal inventor of gyty,cATJi)rDrep,Pap test which revolutionized screening for cervical cancer accounting for —70% of the world market for cervical cancer screening. Cytyc was acquired by Hologic for $6.2 billion in 2007.
  • Founder of EXACT Sciences Corp. (NASDAQ:EXAS and served as CEO and Chairman. EXACT pioneered high-accuracy non-invasive testing for early detection of colorectal cancer. Since the commercial introduction of the company's Cologuard test, EXACT has been the most rapidly growing company in the history of the diagnostics industry.
  • Stan holds 37 US patents.
  • Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer.
  • He currently serves as a director of a number of public and private medical device and diagnostics companies.

Harvey Buck

Advisor
  • Roche Diabetes Care –
    • the electrochemical glucose meter
  • Boehringer Mannheim
  • Miles Laboratories
  • Inventor on Roche Electrochemistry patents

Werner Kuhr

Advisor
  • Director of the Center for Entrepreneurship, Colorado School of Mines
  • Technology Commercialization Director and the founding Director of the Stevens Venture Center
  • Professor Adjoint of Chemistry University of Colorado where he developed electrochemical methods and microfluidic devices
  • Vice President of Research at ZettaCore, Inc., a company he founded and sold into the semiconductor and printed circuit board industry.
  • At UC Riverside, he ran a research program that graduated 25 Ph.D. and MS students in fifteen years, published roughly 100 papers (H-index = 60)
  • He has participated in the formation of five start-up technology companies, several of which were based on translation research in protein diagnostics and genomics

Chuck Henry

Advisor
  • Professor of Chemistry and Chemical & Biological Engineering 18 years
  • Chair of the Department of Chemistry (since 2014).
  • Dr. Henry’s research interests lie broadly in the development of lab-on-a-chip technologies
  • Major techniques used include microfabrication, chromatography, electrochemistry, electrophoresis, microfluidics, microscopy, and 3D printing, paper based diagnostic devices
  • Over 120 peer-reviewed publications, 8 patents
  • Editorial board for Analytica Chimica Acta.
  • Five spin-out companies from Colorado State University

Tomorrows tests today

Save lives by providing actionable information.

Help each cancer patient constantly receive optimal treatment by supplying overnight and ultimately immediate on-site results.